‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies?
Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor types. These therapies, however, carry the risk of ex...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/12/e006073.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129457245847552 |
|---|---|
| author | Andrew Furness Juanita Lopez Claire Livings Claire Pettinger Rafael Grochot |
| author_facet | Andrew Furness Juanita Lopez Claire Livings Claire Pettinger Rafael Grochot |
| author_sort | Andrew Furness |
| collection | DOAJ |
| description | Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor types. These therapies, however, carry the risk of exaggerated cytokine-mediated on-target off-tumor adverse events that require highly specialized inpatient facilities. We report here the Royal Marsden experience of treating patients with advanced solid tumors on early phase immune engager clinical trials in a dedicated inpatient facility, focusing specifically on patterns of cytokine-mediated toxicity seen and proposing a risk-mitigation algorithm for the safe, feasible and scalable delivery of these therapies. |
| format | Article |
| id | doaj-art-685e419c10a44010b20b8a8800523aa7 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-685e419c10a44010b20b8a8800523aa72025-08-20T02:32:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-12-01101210.1136/jitc-2022-006073‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies?Andrew Furness0Juanita Lopez1Claire Livings2Claire Pettinger3Rafael Grochot4Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UKDrug Development Unit, Royal Marsden NHS Foundation Trust, London, UKDepartment of Oncology, University of London Saint George`s, London, UKDrug Development Unit, Royal Marsden NHS Foundation Trust, London, UKDrug Development Unit, Royal Marsden NHS Foundation Trust, London, UKImmune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor types. These therapies, however, carry the risk of exaggerated cytokine-mediated on-target off-tumor adverse events that require highly specialized inpatient facilities. We report here the Royal Marsden experience of treating patients with advanced solid tumors on early phase immune engager clinical trials in a dedicated inpatient facility, focusing specifically on patterns of cytokine-mediated toxicity seen and proposing a risk-mitigation algorithm for the safe, feasible and scalable delivery of these therapies.https://jitc.bmj.com/content/10/12/e006073.full |
| spellingShingle | Andrew Furness Juanita Lopez Claire Livings Claire Pettinger Rafael Grochot ‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies? Journal for ImmunoTherapy of Cancer |
| title | ‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies? |
| title_full | ‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies? |
| title_fullStr | ‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies? |
| title_full_unstemmed | ‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies? |
| title_short | ‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies? |
| title_sort | you give me fever are health services ready for immune cell engager therapy in advanced solid malignancies |
| url | https://jitc.bmj.com/content/10/12/e006073.full |
| work_keys_str_mv | AT andrewfurness yougivemefeverarehealthservicesreadyforimmunecellengagertherapyinadvancedsolidmalignancies AT juanitalopez yougivemefeverarehealthservicesreadyforimmunecellengagertherapyinadvancedsolidmalignancies AT clairelivings yougivemefeverarehealthservicesreadyforimmunecellengagertherapyinadvancedsolidmalignancies AT clairepettinger yougivemefeverarehealthservicesreadyforimmunecellengagertherapyinadvancedsolidmalignancies AT rafaelgrochot yougivemefeverarehealthservicesreadyforimmunecellengagertherapyinadvancedsolidmalignancies |